Informationen på dette website er kun beregnet til Sundhedspersoner i Danmark

Søg

Menu

Close

Log indLog udLægemidlerTerapiområderPfizerConnectPfizerConnectArrangementerMaterialerEfteruddannelse
AboutAlopecia AreataLITFULO Mechanism of ActionSALT EvaluationEfficacyALLEGRO-2b/3 Study OverviewScalp Hair ResponsePatient-reported OutcomesEyebrow & Eyelash ResponseBefore & After ImagesSafetyALLEGRO-2b/3 Adverse ReactionsAdditional Safety ConsiderationsGetting StartedDosingScreening & MonitoringSetting Patient ExpectationsResourcesMaterialsVideos
Setting Patient ExpectationsHelp your patients start and continue with LITFULO

Hair growth takes time and patients may respond differently

Patients should be counselled not to stop taking LITFULO without discussing with their doctor[1] 

LITFULO should be taken once a day, every day[1] 

If treatment interruption is needed, the risk of significant loss of regrown scalp hair after a temporary interruption (<6 weeks) is low[1] 

The benefit-risk of treatment should be reassessed at regular intervals on an individual basis. Consideration should be given to discontinuing patients who show no evidence of therapeutic benefit after 36 weeks of treatment with LITFULO[1] 

ReferencesReference:1. LITFULO (ritlecitinib) SmPC. 
 Indication Litfulo® (ritlecitinib):
 Litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.
[Litfulo SmPC] 
 Litfulo pligttekst
Getting Started Explore safety data Safety Loading

Bivirkninger skal indberettes. Hvis du vil rapportere en bivirkning, kan du kontakte Pfizer på e-mail: [email protected]

 

PfizerPro kontoPfizerPro konto

Få adgang til information, materialer, efteruddannelse samt modtag kommunikation om Pfizers lægemidler og vacciner.

Log indRegisterMin profilLog ud

Informationen på dette website er kun beregnet til Sundhedspersoner i Danmark.

Denne hjemmeside er udarbejdet til dig af Pfizer Danmark.

 

© Pfizer 2023. Alle rettigheder til denne hjemmeside forbeholdes Pfizer ApS.

12 August 2025 * PP-LGF-DNK-0008
Du forlader nu Pfizer
Du forlader nu et Pfizer-drevet website. Links til alle eksterne websites leveres som en ressource til vores besøgende. Pfizer påtager sig intet ansvar for indholdet af websites, der ikke ejes og drives af Pfizer.